<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.1" specific-use="sps-1.9" article-type="case-report" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">dic</journal-id>
      <journal-title-group>
        <journal-title>ABC Imagem Cardiovascular</journal-title>
        
        <abbrev-journal-title abbrev-type="publisher">Arq Bras Cardiol: Imagem cardiovasc</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2675-312X</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia</publisher-name>
        
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.36660/abcimg.20230053i</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Evaluation of Coronary Flow Reserve by Myocardial Scintigraphy in Left Ventricular Hypertrophy</article-title>
      </title-group>
      <contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">0000-0002-5612-4120</contrib-id><name><surname>Felix</surname><given-names>Renata Christian Martins</given-names></name><role>Conception and design of the research</role><role>analysis and interpretation of the data</role><role>writing of the manuscript</role><role>acquisition of data</role><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">0000-0003-3787-8119</contrib-id><name><surname>Pedras</surname><given-names>Felipe Hermely Villela</given-names></name><role> acquisition of data</role><role>obtaining financing</role><role>critical revision of the manuscript for intellectual content</role><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lima</surname><given-names>Odorico de Souza</given-names><suffix>Neto</suffix></name><role>acquisition of data</role><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vitório</surname><given-names>Leonardo Medeiros</given-names></name><role>acquisition of data</role><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group>
      <aff id="aff1"><label>1</label><institution content-type="orgname">Instituto Nacional de Câncer</institution><addr-line><named-content content-type="city">Rio de Janeiro</named-content><named-content content-type="state">RJ</named-content></addr-line><country country="BR">Brazil</country><institution content-type="original">Instituto Nacional de Câncer, Rio de Janeiro, RJ – Brazil</institution></aff>
      <aff id="aff2"><label>2</label><institution content-type="orgname">Clínica de Medicina Nuclear Villela Pedras</institution><addr-line><named-content content-type="city">Rio de Janeiro</named-content><named-content content-type="state">RJ</named-content></addr-line><country country="BR">Brazil</country><institution content-type="original">Clínica de Medicina Nuclear Villela Pedras, Rio de Janeiro, RJ – Brazil</institution></aff>
      <author-notes> <corresp id="c01"> Mailing Address: Renata Christian Martins Félix • Instituto Nacional de Câncer (Inca). Praça da Cruz Vermelha, 23. Postal code: 20230-130. Centro, Rio de Janeiro, RJ – Brazil E-mail: <email>rcmf1973@gmail.com</email> </corresp> <fn fn-type="conflict"> <p>Potential Conflict of Interest</p></fn>  <fn fn-type="current-aff"><p>Renata Christian Martins Félix, Odorico de Souza Lima Neto and Leonardo Medeiros Vitório are collaborators at Clínica Villela Pedras; and Felipe Hermely Villela Pedras is medical director at Clínica Villela Pedras.</p></fn> <fn fn-type="edited-by"><p>Editor responsible for the review: Rafael Lopes</p></fn> </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>26</day>
        <month>09</month>
        <year>2023</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <month>09</month>
        <year>2023</year>
      </pub-date>
      <volume>36</volume>
      <issue>3</issue>
      <elocation-id>e20230053</elocation-id>
      <history><date date-type="received"><day>2</day><month>06</month><year>2023</year></date><date date-type="rev-recd"><day>1</day><month>08</month><year>2023</year></date><date date-type="accepted"><day>7</day><month>08</month><year>2023</year></date></history>
      <permissions>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
<license-p>
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
</license-p>
</license>
</permissions>
      <kwd-group xml:lang="en"><kwd>Myocardial Perfusion Imaging</kwd><kwd>Hypertrophy, Left Ventricular</kwd><kwd>Microvascular Angina</kwd><kwd>Regional Blood Flow</kwd></kwd-group>
      <counts><fig-count count="6"/><table-count count="0"/><equation-count count="0"/><ref-count count="11"/></counts>
    </article-meta>
  </front>
  <body>
<sec sec-type="intro"><title>Introduction</title>
	<p>The microvascular integrity of the myocardial bed can be assessed by coronary flow reserve (CFR), which is a calculation of the ratio between the absolute coronary blood flow under vasodilator stress and under resting conditions. This measurement is capable of estimating vasomotor dysfunction, and it reflects the hemodynamic effect of focal, diffuse, or small-vessel coronary disease.<sup><xref rid="B1" ref-type="bibr">1</xref></sup></p>
	<p>Currently, it is possible to measure CFR invasively using the techniques of thermodilution or intracoronary Doppler and through non-invasive methods, such as echocardiography, magnetic resonance imaging, computed tomography, or nuclear medicine.<sup><xref rid="B1" ref-type="bibr">1</xref></sup></p>
	<p>The gold standard for non-invasive assessment of CFR is positron emission tomography (PET) myocardial perfusion, which has proven to be a valuable diagnostic and prognostic marker in the context of coronary disease and non-obstructive heart diseases.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> Radiotracers used for PET myocardial perfusion are not usually available in many medical centers worldwide, including Brazil, due to the need for complex and costly logistics of production.</p>
	<p>CFR can also be measured by means of conventional myocardial perfusion scintigraphy using special gamma cameras with solid state detectors, known as cadmium-zinc-tellurium (CZT), which are already present in many nuclear medicine services in Brazil. The measurement of CFR using CZT has shown good agreement with PET, and it has a proven impact on prognosis and therapeutic management.<sup><xref rid="B3" ref-type="bibr">3</xref></sup></p>
	<p>We report a clinical case in which the evaluation of CFR through myocardial scintigraphy using a CZT camera proved to be useful in understanding the pathophysiology of the patient’s clinical condition and in stratifying cardiovascular risk.</p>
</sec><sec sec-type="cases"><title>Case presentation</title>
	<p>We report the case of a 42-year-old, White, male patient with hypertension and overweight, who complained of recurrent atypical chest pain.</p>
	<p>He performed an exercise test that presented exclusively electrocardiographic criteria for myocardial ischemia, reaching 95% of the predicted maximum heart rate and 10 metabolic equivalents.</p>
	<p>He was referred for myocardial perfusion scintigraphy under physical exertion, which provided evidence of mild myocardial ischemia in the anteroseptal (middle), latero-apical, and inferolateral (middle) segments, with an estimated ischemic burden of less than 5% of the myocardium.</p>
	<p>The patient underwent coronary cineangiography, which did not reveal coronary obstructions, but identified an extensive myocardial bridge in the territory of the left anterior descending artery, with a maximum systolic constriction of 70% in the distal third, and signs of left ventricular hypertrophy.</p>
	<p>In spite of optimized clinical therapy, the symptoms persisted.</p>
	<p>A new myocardial perfusion scintigraphy was performed with assessment of CFR under pharmacological stress with dipyridamole, which provided evidence of pronounced myocardial ischemia of the left ventricle including segments of the apical, lateral, and inferior walls. A relative increase in radiotracer uptake was observed in the apical wall of the left ventricle on the resting images, suggestive of asymmetric ventricular hypertrophy (<xref rid="f01" ref-type="fig">Figure 1</xref>).</p><p><fig id="f01"><label>Figure 1</label><caption><title>– Myocardial perfusion scintigraphy. *Images in three axes: short, vertical, and horizontal, respectively. The upper and middle rows show sections in the stress and resting phase with the patient in the supine position, and the bottom row shows sections in the prone position during the stress phase. Short arrows demonstrate areas of perfusion defect in the inferior wall of the left ventricle. The long arrows indicate the relative increase in radiotracer uptake in the apical wall in resting images.</title></caption><graphic xlink:href="2675-312X-dic-36-03-e20230053-gf01.jpg"/></fig></p>
	<p>CFR assessment (<xref rid="f02" ref-type="fig">Figure 2</xref>) revealed decreased CFR in all vascular territories and reduced total CFR with a value of 0.97, applying values greater than 2.1 as a reference for normality.<sup><xref rid="B4" ref-type="bibr">4</xref></sup></p><p><fig id="f02"><label>Figure 2</label><caption><title>– CFR assessment. * Upper right: Absolute values of myocardial blood flow under stress and at rest and flow reserve by vascular territory and global reserve. LAD: left anterior descending artery; LCX: left circumflex artery; RCA: right coronary artery; TOT: total values of the left ventricular myocardium. Bottom left: Polar maps condense myocardial perfusion under stress and at rest in the 17 myocardial segments. Reversibility highlights the area of myocardial ischemia. Bottom right: Myocardial radiotracer activity curves over time by vascular territory and globally under stress and at rest.</title></caption><graphic xlink:href="2675-312X-dic-36-03-e20230053-gf02.jpg"/></fig></p>
	<p>A subsequent echocardiographic study confirmed the presence of important mid-apical hypertrophy of the left ventricle, suggestive of Yamaguchi syndrome (<xref rid="f03" ref-type="fig">Figure 3</xref>).</p><p><fig id="f03"><label>Figure 3</label><caption><title>– Longitudinal two-chamber echocardiogram demonstrating mid-apical left ventricular hypertrophy (arrow).</title></caption><graphic xlink:href="2675-312X-dic-36-03-e20230053-gf03.jpg"/></fig></p>
</sec><sec sec-type="discussion"><title>Discussion</title>
	<p>More than 20% of patients with angina who undergo invasive assessment of coronary anatomy do not have significant obstructive lesions. However, in the majority of cases, it is possible to identify factors that justify the symptom, such as myocardial bridge or signs of microvascular disease.<sup><xref rid="B5" ref-type="bibr">5</xref></sup></p>
	<p>Dysfunction of coronary microcirculation has been shown to play a key role in the development and evolution of a series of cardiovascular conditions, whether in obstructive or non-obstructive atherosclerosis, as well as cardiomyopathies of diverse etiologies.<sup><xref rid="B6" ref-type="bibr">6</xref></sup></p>
	<p>Hypertrophic heart disease is a disease of genetic etiology characterized by thickening of the left ventricular wall. It manifests concentrically or asymmetrically, as in apical hypertrophy, also known as Yamaguchi syndrome. Although it is more prevalent among Asian patients, it can be found in up to 10% of cases of left ventricular hypertrophy in patients who are not Asian. Patients with apical hypertrophy may present atrial fibrillation, chest pain, pulmonary hypertension, or ventricular arrhythmias, in addition to an annual mortality rate of up to 4%.<sup><xref rid="B7" ref-type="bibr">7</xref></sup></p>
	<p>Although magnetic resonance has greater diagnostic sensitivity, echocardiography identifies the disease in the majority of cases, and it can determine prognostic factors, such as the presence of diastolic dysfunction or apical aneurysm.<sup><xref rid="B8" ref-type="bibr">8</xref></sup></p>
	<p>Myocardial ischemia is a recurrent finding, and it may occur with loss of myocytes and fibrosis. More than the increased demand for oxygen by the hypertrophied myocardium, it is known that structural changes in small vessels are the primary mechanism of perfusion deficit. Thus, damage to the coronary microcirculation is at the core of the ischemic substrate of hypertrophic heart disease.<sup><xref rid="B6" ref-type="bibr">6</xref></sup></p>
	<p>Studies on the assessment of flow reserve in hypertrophic heart disease have demonstrated the presence of altered CFR, even in areas without hypertrophy, and it plays an important role in prognostic evaluation as a predictor of clinical deterioration, systolic dysfunction, and death, related to the degree of alteration in coronary flow.<sup><xref rid="B9" ref-type="bibr">9</xref></sup></p>
	<p>In addition to apical ventricular hypertrophy, the patient in this case had a myocardial bridge, a congenital anomaly that determines the intramural course of the coronary epicardial artery. The clinical significance of the myocardial bridge is questionable, considering that it is a systolic compression of the vessel wall, whereas myocardial perfusion is a phenomenon that mainly occurs in diastole. However, the association with ventricular hypertrophy is a determinant additional factor for it reducing myocardial flow reserve and being the cause of angina in these cases.<sup><xref rid="B10" ref-type="bibr">10</xref></sup></p>
	<p>Evidence has demonstrated that patients with very low global CFR, less than 1.5, without obstructive coronary disease, constitute a high-risk group for cardiovascular events. Unfortunately, the strategies that can alter this clinical outcome are not clear, considering that the pathophysiological mechanisms involved are not completely known.<sup><xref rid="B11" ref-type="bibr">11</xref></sup></p>
	<p>The assessment of CFR in patients with hypertrophic heart disease, as in the case reported, as well as in other scenarios such as metabolic syndrome, cardio-oncological complications associated with chemotherapy, and heart failure with preserved ejection fraction, identifies the pathophysiological substrate that justifies the patient’s clinical condition, stratifies risk, and indicates patients who may benefit from the intensification of the available clinical arsenal with the aim of modifying unfavorable prognosis.<sup><xref rid="B11" ref-type="bibr">11</xref></sup></p>
</sec></body>
  <back> <ref-list><title>References</title> <ref id="B1"><label>1</label><mixed-citation>. Gould KL. Does Coronary Flow Trump Coronary Anatomy? JACC Cardiovasc Imaging. 2009;2(8):1009-23. doi: 10.1016/j.jcmg.2009.06.004.</mixed-citation><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gould</surname><given-names>KL</given-names></name></person-group><article-title>Does Coronary Flow Trump Coronary Anatomy?</article-title><source>JACC Cardiovasc Imaging</source><year>2009</year><volume>2</volume><issue>8</issue><fpage>1009</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2009.06.004</pub-id></element-citation></ref> <ref id="B2"><label>2</label><mixed-citation>. Gould KL, Johnson NP, Bateman TM, Beanlands RS, Bengel FM, Bober R, et al. Anatomic Versus Physiologic Assessment of Coronary Artery Disease. Role of Coronary Flow Reserve, Fractional Flow Reserve, and Positron Emission Tomography Imaging in Revascularization Decision-Making. J Am Coll Cardiol. 2013;62(18):1639-53. doi: 10.1016/j.jacc.2013.07.076.</mixed-citation><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gould</surname><given-names>KL</given-names></name><name><surname>Johnson</surname><given-names>NP</given-names></name><name><surname>Bateman</surname><given-names>TM</given-names></name><name><surname>Beanlands</surname><given-names>RS</given-names></name><name><surname>Bengel</surname><given-names>FM</given-names></name><name><surname>Bober</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Anatomic Versus Physiologic Assessment of Coronary Artery Disease. Role of Coronary Flow Reserve, Fractional Flow Reserve, and Positron Emission Tomography Imaging in Revascularization Decision-Making</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>62</volume><issue>18</issue><fpage>1639</fpage><lpage>1653</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2013.07.076</pub-id></element-citation></ref> <ref id="B3"><label>3</label><mixed-citation>. Petretta M, Storto G, Pellegrino T, Bonaduce D, Cuocolo A. Quantitative Assessment of Myocardial Blood Flow with SPECT. Prog Cardiovasc Dis. 2015;57(6):607-14. doi: 10.1016/j.pcad.2014.12.007.</mixed-citation><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petretta</surname><given-names>M</given-names></name><name><surname>Storto</surname><given-names>G</given-names></name><name><surname>Pellegrino</surname><given-names>T</given-names></name><name><surname>Bonaduce</surname><given-names>D</given-names></name><name><surname>Cuocolo</surname><given-names>A</given-names></name></person-group><article-title>Quantitative Assessment of Myocardial Blood Flow with SPECT</article-title><source>Prog Cardiovasc Dis</source><year>2015</year><volume>57</volume><issue>6</issue><fpage>607</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1016/j.pcad.2014.12.007</pub-id></element-citation></ref> <ref id="B4"><label>4</label><mixed-citation>. Agostini D, Roule V, Nganoa C, Roth N, Baavour R, Parienti JJ, et al. First Validation of Myocardial Flow Reserve Assessed by Dynamic 99mTc-sestamibi CZT-SPECT Camera: Head to Head Comparison with 15O-Water PET and Fractional Flow Reserve in Patients with Suspected Coronary Artery Disease. The WATERDAY Study. Eur J Nucl Med Mol Imaging. 2018;45(7):1079-90. doi: 10.1007/s00259-018-3958-7.</mixed-citation><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostini</surname><given-names>D</given-names></name><name><surname>Roule</surname><given-names>V</given-names></name><name><surname>Nganoa</surname><given-names>C</given-names></name><name><surname>Roth</surname><given-names>N</given-names></name><name><surname>Baavour</surname><given-names>R</given-names></name><name><surname>Parienti</surname><given-names>JJ</given-names></name><etal>et al</etal></person-group><article-title>First Validation of Myocardial Flow Reserve Assessed by Dynamic 99mTc-sestamibi CZT-SPECT Camera: Head to Head Comparison with 15O-Water PET and Fractional Flow Reserve in Patients with Suspected Coronary Artery Disease. The WATERDAY Study</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2018</year><volume>45</volume><issue>7</issue><fpage>1079</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1007/s00259-018-3958-7</pub-id></element-citation></ref> <ref id="B5"><label>5</label><mixed-citation>. Lee BK, Lim HS, Fearon WF, Yong AS, Yamada R, Tanaka S, et al. Invasive Evaluation of Patients with Angina in the Absence of Obstructive Coronary Artery Disease. Circulation. 2015;131(12):1054-60. doi: 10.1161/CIRCULATIONAHA.114.012636.</mixed-citation><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>BK</given-names></name><name><surname>Lim</surname><given-names>HS</given-names></name><name><surname>Fearon</surname><given-names>WF</given-names></name><name><surname>Yong</surname><given-names>AS</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Invasive Evaluation of Patients with Angina in the Absence of Obstructive Coronary Artery Disease</article-title><source>Circulation</source><year>2015</year><volume>131</volume><issue>12</issue><fpage>1054</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.012636</pub-id></element-citation></ref> <ref id="B6"><label>6</label><mixed-citation>. Del Buono MG, Montone RA, Camilli M, Carbone S, Narula J, Lavie CJ, et al. Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;78(13):1352-1371. doi: 10.1016/j.jacc.2021.07.042.</mixed-citation><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Buono</surname><given-names>MG</given-names></name><name><surname>Montone</surname><given-names>RA</given-names></name><name><surname>Camilli</surname><given-names>M</given-names></name><name><surname>Carbone</surname><given-names>S</given-names></name><name><surname>Narula</surname><given-names>J</given-names></name><name><surname>Lavie</surname><given-names>CJ</given-names></name><etal>et al</etal></person-group><article-title>Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review</article-title><source>J Am Coll Cardiol</source><year>2021</year><volume>78</volume><issue>13</issue><fpage>1352</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.07.042</pub-id></element-citation></ref> <ref id="B7"><label>7</label><mixed-citation>. Klarich KW, Jost CHA, Binder J, Connolly HM, Scott CG, Freeman WK, et al. Risk of Death in Long-Term Follow-Up of Patients with Apical Hypertrophic Cardiomyopathy. Am J Cardiol. 2013;111(12):1784-91. doi: 10.1016/j.amjcard.2013.02.040.</mixed-citation><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klarich</surname><given-names>KW</given-names></name><name><surname>Jost</surname><given-names>CHA</given-names></name><name><surname>Binder</surname><given-names>J</given-names></name><name><surname>Connolly</surname><given-names>HM</given-names></name><name><surname>Scott</surname><given-names>CG</given-names></name><name><surname>Freeman</surname><given-names>WK</given-names></name><etal>et al</etal></person-group><article-title>Risk of Death in Long-Term Follow-Up of Patients with Apical Hypertrophic Cardiomyopathy</article-title><source>Am J Cardiol</source><year>2013</year><volume>111</volume><issue>12</issue><fpage>1784</fpage><lpage>1791</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2013.02.040</pub-id></element-citation></ref> <ref id="B8"><label>8</label><mixed-citation>. Hughes RK, Knott KD, Malcolmson J, Augusto JB, Mohiddin SA, Kellman P, et al. Apical Hypertrophic Cardiomyopathy: The Variant Less Known. J Am Heart Assoc. 2020;9(5):e015294. doi: 10.1161/JAHA.119.015294.</mixed-citation><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>RK</given-names></name><name><surname>Knott</surname><given-names>KD</given-names></name><name><surname>Malcolmson</surname><given-names>J</given-names></name><name><surname>Augusto</surname><given-names>JB</given-names></name><name><surname>Mohiddin</surname><given-names>SA</given-names></name><name><surname>Kellman</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Apical Hypertrophic Cardiomyopathy: The Variant Less Known</article-title><source>J Am Heart Assoc</source><year>2020</year><volume>9</volume><issue>5</issue><elocation-id>e015294</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.119.015294</pub-id></element-citation></ref> <ref id="B9"><label>9</label><mixed-citation>. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary Microvascular Dysfunction and Prognosis in Hypertrophic Cardiomyopathy. N Engl J Med. 2003;349(11):1027-35. doi: 10.1056/NEJMoa025050.</mixed-citation><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cecchi</surname><given-names>F</given-names></name><name><surname>Olivotto</surname><given-names>I</given-names></name><name><surname>Gistri</surname><given-names>R</given-names></name><name><surname>Lorenzoni</surname><given-names>R</given-names></name><name><surname>Chiriatti</surname><given-names>G</given-names></name><name><surname>Camici</surname><given-names>PG</given-names></name></person-group><article-title>Coronary Microvascular Dysfunction and Prognosis in Hypertrophic Cardiomyopathy</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><issue>11</issue><fpage>1027</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa025050</pub-id></element-citation></ref> <ref id="B10"><label>10</label><mixed-citation>. Tarantini G, Migliore F, Cademartiri F, Fraccaro C, Iliceto S. Left Anterior Descending Artery Myocardial Bridging: A Clinical Approach. J Am Coll Cardiol. 2016;68(25):2887-99. doi: 10.1016/j.jacc.2016.09.973.</mixed-citation><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarantini</surname><given-names>G</given-names></name><name><surname>Migliore</surname><given-names>F</given-names></name><name><surname>Cademartiri</surname><given-names>F</given-names></name><name><surname>Fraccaro</surname><given-names>C</given-names></name><name><surname>Iliceto</surname><given-names>S</given-names></name></person-group><article-title>Left Anterior Descending Artery Myocardial Bridging: A Clinical Approach</article-title><source>J Am Coll Cardiol</source><year>2016</year><volume>68</volume><issue>25</issue><fpage>2887</fpage><lpage>2899</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2016.09.973</pub-id></element-citation></ref> <ref id="B11"><label>11</label><mixed-citation>. Taqueti VR, Di Carli MF. Clinical Significance of Noninvasive Coronary Flow Reserve Assessment in Patients with Ischemic Heart Disease. Curr Opin Cardiol. 2016;31(6):662-9. doi: 10.1097/HCO.0000000000000339.</mixed-citation><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taqueti</surname><given-names>VR</given-names></name><name><surname>Di Carli</surname><given-names>MF</given-names></name></person-group><article-title>Clinical Significance of Noninvasive Coronary Flow Reserve Assessment in Patients with Ischemic Heart Disease</article-title><source>Curr Opin Cardiol</source><year>2016</year><volume>31</volume><issue>6</issue><fpage>662</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1097/HCO.0000000000000339</pub-id></element-citation></ref> </ref-list><fn-group><fn fn-type="other"> <p>Study Association</p> <p>This study is not associated with any thesis or dissertation work.</p></fn><fn fn-type="other"> <p>Ethics Approval and Consent to Participate</p> <p>This study was approved by the Ethics Committee of the Instituto Nacional de Cardiologia under the protocol number 67072022.3.000.5272. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.</p></fn><fn fn-type="supported-by"> <p>Sources of Funding: This study was funded by por Clínica de Medicina Nuclear Villela Pedras.</p></fn></fn-group></back>
  <sub-article article-type="translation" id="TRpt" xml:lang="pt">
    <front-stub>
      <article-id pub-id-type="doi">10.36660/abcimg.20230053</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Avaliação de Reserva de Fluxo Coronariano Pela Cintilografia Miocárdica na Hipertrofia Ventricular Esquerda</article-title>
      </title-group>
      <contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">0000-0002-5612-4120</contrib-id><name><surname>Felix</surname><given-names>Renata Christian Martins</given-names></name><role> Concepção e desenho da pesquisa</role><role>análise e interpretação dos dados</role><role>redação do manuscrito</role><role>obtenção de dados</role><xref ref-type="aff" rid="aff1002"><sup>1</sup></xref><xref ref-type="aff" rid="aff2002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">0000-0003-3787-8119</contrib-id><name><surname>Pedras</surname><given-names>Felipe Hermely Villela</given-names></name><role> obtenção de dados</role><role>obtenção de financiamento</role><role>revisão crítica do manuscrito quanto ao conteúdo intelectual importante</role><xref ref-type="aff" rid="aff2002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lima</surname><given-names>Odorico de Souza</given-names><suffix>Neto</suffix></name><role>obtenção de dados</role><xref ref-type="aff" rid="aff2002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vitório</surname><given-names>Leonardo Medeiros</given-names></name><role>obtenção de dados</role><xref ref-type="aff" rid="aff2002"><sup>2</sup></xref></contrib></contrib-group>
      <aff id="aff1002"><label>1</label><country country="BR">Brasil</country><institution content-type="original">Instituto Nacional de Câncer, Rio de Janeiro, RJ – Brasil</institution></aff>
      <aff id="aff2002"><label>2</label><country country="BR">Brasil</country><institution content-type="original">Clínica de Medicina Nuclear Villela Pedras, Rio de Janeiro, RJ – Brasil</institution></aff>
      <author-notes> <corresp id="c01002"> Correspondência: Renata Christian Martins Félix • Instituto Nacional de Câncer (Inca). Praça da Cruz Vermelha, 23. CEP: 20230-130. Centro, Rio de Janeiro, RJ – Brasil E-mail: rcmf1973@gmail.com </corresp> <fn id="fn1002" fn-type="conflict"> <p>Potencial Conflito de Interesse</p></fn><fn id="fn2002" fn-type="current-aff"> <p>Renata Christian Martins Félix, Odorico de Souza Lima Neto e Leonardo Medeiros Vitório são prestadores de serviço da Clínica Villela Pedras; e Felipe Hermely Villela Pedras é diretor médico da Clínica Villela Pedras.</p></fn><fn id="fn3002" fn-type="edited-by"> <p>Editor responsável pela revisão: Rafael Lopes</p></fn> </author-notes>
      <kwd-group xml:lang="pt"><kwd>Imagem de Perfusão do Miocárdio</kwd><kwd>Hipertrofia Ventricular Esquerda</kwd><kwd>Angina microvascular</kwd><kwd>Fluxo sanguíneo Regional</kwd></kwd-group>
    </front-stub>
    <body>
<sec sec-type="intro"><title>Introdução</title>
	<p>A integridade microvascular do leito miocárdico pode ser avaliada pela reserva de fluxo coronariano (CFR), que é um cálculo da proporção entre o fluxo sanguíneo coronariano absoluto sob estresse vasodilatador e em condições de repouso. Sua medida é capaz de estimar a disfunção vasomotora e reflete o efeito hemodinâmico de doença coronariana focal, difusa ou de pequenos vasos.<sup><xref rid="B1" ref-type="bibr">1</xref></sup></p>
	<p>Atualmente, é possível medir a CFR de forma invasiva pela técnica de termodiluição ou Doppler intracoronariano e através de métodos não-invasivos, como ecocardiograma, ressonância magnética, tomografia computadorizada ou técnicas de medicina nuclear.<sup><xref rid="B1" ref-type="bibr">1</xref></sup></p>
	<p>O padrão-ouro para a avaliação não invasiva da CFR é a perfusão miocárdica através da tomografia por emissão de pósitrons (PET), que tem se mostrado como valioso marcador diagnóstico e prognóstico no contexto da doença coronária e de cardiopatias não obstrutivas.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> Radiotraçadores utilizados para perfusão miocárdica pela PET não são habitualmente disponíveis em muitos centros médicos pelo mundo, inclusive no Brasil, devido à necessidade de uma complexa e dispendiosa logística de produção.</p>
	<p>A medida da CFR também pode ser realizada através da cintilografia de perfusão miocárdica convencional utilizando gama-câmaras especiais com detectores em estado sólido, conhecidos como cádmio-zinco-telúrio (CZT), que já estão presentes em muitos serviços de medicina nuclear em nosso país. A medida da CFR pela CZT tem demonstrado boa concordância com a PET e tem provado impacto prognóstico e no manejo terapêutico.<sup><xref rid="B3" ref-type="bibr">3</xref></sup></p>
	<p>Relatamos um caso clínico em que a avaliação da CFR através da cintilografia miocárdica em câmara CZT se mostrou útil na compreensão da fisiopatologia do quadro clínico do paciente e na estratificação de risco cardiovascular.</p>
</sec>
<sec sec-type="cases"><title>Apresentação do caso</title>
	<p>Homem branco, de 42 anos, hipertenso e com sobrepeso, apresenta queixa de dor precordial atípica recorrente.</p>
	<p>Realizou teste ergométrico que apresentou critérios exclusivamente eletrocardiográficos para isquemia miocárdica, tendo alcançado 95% da frequência cardíaca máxima prevista e 10 METs.</p>
	<p>Foi encaminhado à cintilografia de perfusão miocárdica sob esforço físico que evidenciou discreta isquemia miocárdica nos segmentos ântero-septal (médio), látero-apical e ínfero-lateral (médio), com carga isquêmica estimada em menos de 5% do miocárdio.</p>
	<p>O paciente foi submetido a cineangiocoronariografia que não revelou obstruções coronarianas, mas identificou extensa ponte miocárdica no território da artéria descendente anterior, com constrição sistólica máxima de 70% no terço distal, e sinais de hipertrofia ventricular esquerda.</p>
	<p>Apesar de terapêutica clínica otimizada, houve persistência da sintomatologia.</p>
	<p>Foi realizada nova cintilografia de perfusão miocárdica com avaliação de CFR sob estresse farmacológico com dipiridamol, que evidenciou isquemia miocárdica acentuada do ventrículo esquerdo compreendendo segmentos das paredes apical, lateral e inferior. Notou-se aumento relativo da captação do radiotraçador na parede apical do ventrículo esquerdo nas imagens de repouso, sugestivo de hipertrofia ventricular assimétrica (<xref rid="f01002" ref-type="fig">Figura 1</xref>).</p><p><fig id="f01002"><label>Figura 1</label><caption><title>– Cintilografia de perfusão miocárdica. Imagens em três eixos: curto, longitudinal vertical e horizontal, respectivamente. Nas linhas superior e do meio, cortes na fase de estresse e de repouso em posição supina e, na linha inferior, cortes na posição prona na fase de estresse. As setas curtas demonstram áreas de defeito perfusional na parede inferior do ventrículo esquerdo. As setas longas apontam o aumento relativo da captação do radiotraçador na parede apical nas imagens de repouso.</title></caption><graphic xlink:href="2675-312X-dic-36-03-e20230053-gf01-pt.jpg"/></fig></p>
	<p>A análise da CFR (<xref rid="f02002" ref-type="fig">Figura 2</xref>) revelou diminuição desta em todos os territórios vasculares e redução total com valor de 0,97, tendo como referência da normalidade valor superior a 2,1.<sup><xref rid="B4" ref-type="bibr">4</xref></sup></p><p><fig id="f02002"><label>Figura 2</label><caption><title>– Avaliação de CFR. * Canto superior à direita: valores absolutos do fluxo sanguíneo miocárdio em estresse e repouso e da reserva de fluxo por território vascular e global. LAD: artéria descendente anterior; LCX: artéria circunflexa; RCA: artéria coronária direita; TOT: valores globais do miocárdio do ventrículo esquerdo. Canto inferior à esquerda: mapas polares condensam a perfusão miocárdica em estresse e em repouso nos 17 segmentos miocárdios. Reversibility destaca a área de isquemia miocárdica. Canto inferior à direita: curvas da atividade do radiotraçador no miocárdio ao longo do tempo por território vascular e global em estresse e em repouso.</title></caption><graphic xlink:href="2675-312X-dic-36-03-e20230053-gf02-pt.jpg"/></fig></p>
	<p>Estudo ecocardiográfico realizado posteriormente confirmou a presença de importante hipertrofia médio-apical do ventrículo esquerdo, sugestivo de síndrome de Yamaguchi (<xref rid="f03002" ref-type="fig">Figura 3</xref>).</p><p><fig id="f03002"><label>Figura 3</label><caption><title>– Ecocardiograma em corte longitudinal duas câmaras demonstrando hipertrofia médio-apical do ventrículo esquerdo (seta).</title></caption><graphic xlink:href="2675-312X-dic-36-03-e20230053-gf03-pt.jpg"/></fig></p>
</sec>
<sec sec-type="discussion"><title>Discussão</title>
	<p>Mais de 20% dos pacientes com angina que realizam avaliação invasiva da anatomia coronariana não apresentam lesões obstrutivas significativas. No entanto, na maioria dos casos, é possível identificar fatores que justifiquem o sintoma, tais como ponte miocárdica ou sinais de doença microvascular.<sup><xref rid="B5" ref-type="bibr">5</xref></sup></p>
	<p>A disfunção da microcirculação coronariana tem demonstrado ter papel chave no desenvolvimento e na evolução de uma série de condições cardiovasculares, seja na aterosclerose obstrutiva ou não-obstrutiva, assim como nas cardiomiopatias de etiologias diversas.<sup><xref rid="B6" ref-type="bibr">6</xref></sup></p>
	<p>A cardiopatia hipertrófica é uma doença de etiologia genética caracterizada pelo espessamento da parede ventricular esquerda, e se manifesta de forma concêntrica ou assimétrica, como na hipertrofia apical, também conhecida como síndrome de Yamaguchi. Embora mais prevalente entre asiáticos, pode ser encontrada em até 10% dos casos de hipertrofia ventricular esquerda em não asiáticos. Os pacientes com hipertrofia apical podem apresentar fibrilação atrial, dor torácica, hipertensão pulmonar ou arritmias ventriculares, além de taxa de mortalidade anual de até 4%.<sup><xref rid="B7" ref-type="bibr">7</xref></sup></p>
	<p>Embora a ressonância magnética apresente maior sensibilidade diagnóstica, o ecocardiograma identifica a doença na maioria dos casos e pode determinar fatores prognósticos, como a presença de disfunção diastólica ou aneurisma apical.<sup><xref rid="B8" ref-type="bibr">8</xref></sup></p>
	<p>Isquemia miocárdica é um achado recorrente, podendo cursar com perda de miócitos e fibrose. Mais do que a demanda aumentada de oxigênio pelo miocárdio hipertrofiado, sabe-se que alterações estruturais de pequenos vasos é o mecanismo primário de déficit perfusional. Assim, o dano da microcirculação coronariana está no cerne do substrato isquêmico da cardiopatia hipertrófica.<sup><xref rid="B6" ref-type="bibr">6</xref></sup></p>
	<p>Estudos de avaliação de reserva de fluxo na cardiopatia hipertrófica demonstram a presença de alteração da CFR mesmo em áreas sem hipertrofia e tem importante papel na avaliação prognóstica como preditor de deterioração clínica, disfunção sistólica e morte, relacionado ao grau de alteração do fluxo coronariano.<sup><xref rid="B9" ref-type="bibr">9</xref></sup></p>
	<p>Além de hipertrofia ventricular apical, o paciente deste caso apresenta ponte miocárdica, uma anomalia congênita que determina percurso intramural de artéria epicárdica coronariana. O significado clínico da ponte miocárdica é questionável, considerando-se que se trata de compressão sistólica da parede do vaso enquanto a perfusão miocárdica é um fenômeno que ocorre principalmente na diástole. No entanto, a associação com hipertrofia ventricular é fator somatório determinante para reduzir a reserva de fluxo miocárdio e ser a causa da angina nestes casos.<sup><xref rid="B10" ref-type="bibr">10</xref></sup></p>
	<p>Evidências têm demonstrado que pacientes com CFR global muito baixa, inferior a 1,5, sem doença coronariana obstrutiva, constituem um grupo de alto risco para eventos cardiovasculares. Infelizmente, as estratégias que podem alterar este desfecho clínico não estão claras, considerando que os mecanismos fisiopatológicos envolvidos não são completamente conhecidos.<sup><xref rid="B11" ref-type="bibr">11</xref></sup></p>
	<p>A avaliação da CFR em pacientes com cardiopatia hipertrófica, como no caso relatado, assim como em outros cenários como síndrome metabólica, complicações cardio-oncológicas associadas a quimioterápicos e insuficiência cardíaca de fração de ejeção preservada, identifica o substrato fisiopatológico que justifica o quadro clínico do paciente, estratifica o risco e sinaliza aqueles que podem se beneficiar da intensificação do arsenal clínico disponível com o intuito de modificação do prognóstico desfavorável. <sup><xref rid="B11" ref-type="bibr">11</xref></sup></p>
</sec></body>
    <back> <fn-group> <fn fn-type="other"> <p>Vinculação Acadêmica</p> <p>Não há vinculação deste estudo a programas de pós-graduação.</p></fn> <fn id="fn4002" fn-type="other"> <p>Aprovação Ética e Consentimento Informado</p> <p>Este estudo foi aprovado pelo Comitê de Ética do Instituto Nacional de Cardiologia sob o número de protocolo 67072022.3.000.5272. Todos os procedimentos envolvidos nesse estudo estão de acordo com a Declaração de Helsinki de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes incluídos no estudo.</p></fn>  <fn fn-type="supported-by" id="fn6002"> <p>Fontes de Financiamento: O presente estudo foi financiado por Clínica de Medicina Nuclear Villela Pedras.</p></fn> </fn-group> </back>
  </sub-article>
</article>
